Your browser doesn't support javascript.
loading
Opioid Use Disorder Among Clients of Community Mental Health Clinics: Prevalence, Characteristics, and Treatment Willingness.
Ober, Allison J; Hunter, Sarah B; McCullough, Colleen M; Leamon, Isabel; McCreary, Michael; Beas, Ivan; Montero, Alanna; Tarn, Derjung M; Bromley, Elizabeth; Hurley, Brian; Sheehe, John; Martinez, Jeremy; Watkins, Katherine E.
Afiliación
  • Ober AJ; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Hunter SB; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • McCullough CM; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Leamon I; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • McCreary M; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Beas I; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Montero A; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Tarn DM; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Bromley E; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Hurley B; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Sheehe J; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Martinez J; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
  • Watkins KE; RAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles
Psychiatr Serv ; 73(3): 271-279, 2022 Mar 01.
Article en En | MEDLINE | ID: mdl-34281359
ABSTRACT

OBJECTIVE:

The authors examined the prevalence of co-occurring opioid use disorder and willingness to engage in treatment among clients of eight Los Angeles County Department of Mental Health outpatient clinics.

METHODS:

Adults presenting for an appointment over a 2-week period were invited to complete a voluntary, anonymous health survey. Clients who indicated opioid use in the past year were offered a longer survey assessing probable opioid use disorder. Willingness to take medication and receive treatment also was assessed.

RESULTS:

In total, 3,090 clients completed screening. Among these, 8% had a probable prescription (Rx) opioid use disorder and 2% a probable heroin use disorder. Of the clients with probable Rx opioid use or heroin use disorder, 49% and 25% were female, respectively. Among those with probable Rx opioid use disorder, 43% were Black, 33% were Hispanic, and 12% were White, and among those with probable heroin use disorder, 24% were Black, 22% were Hispanic, and 39% were White. Seventy-eight percent of those with Rx opioid use disorder had never received any treatment, and 82% had never taken a medication for this disorder; 39% of those with heroin use disorder had never received any treatment, and 39% had never received a medication. The strongest predictor of willingness to take a medication was believing that it would help stop opioid use (buprenorphine, ß=13.54, p=0.003, and naltrexone long-acting injection, ß=15.83, p<0.001).

CONCLUSIONS:

These findings highlight the need to identify people with opioid use disorder and to educate clients in mental health settings about medications for these disorders.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Buprenorfina / Trastornos Relacionados con Opioides Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Psychiatr Serv Asunto de la revista: PSIQUIATRIA Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Buprenorfina / Trastornos Relacionados con Opioides Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Psychiatr Serv Asunto de la revista: PSIQUIATRIA Año: 2022 Tipo del documento: Article